Tech
Palantir wins a three-year deal worth $44.4M with the FDA to use Palantir software to power drug reviews and inspections, including possible COVID-19 treatments (Lizette Chapman/Bloomberg)
[ad_1]
Lizette Chapman / Bloomberg:
Palantir wins a three-year deal worth $44.4M with the FDA to use Palantir software to power drug reviews and inspections, including possible COVID-19 treatments — Palantir Technologies Inc. won a deal with the U.S. Food and Drug Administration to help power drug reviews and inspections …
[ad_2]
Source link
